Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Ind-Swift Laboratories

+50.15% revenue YoY

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Standalone only, unaudited

Reported revenue (₹ crore, except EPS in ₹/share): 234.89

Read summary and comparison caveats

On a standalone basis, Ind-Swift Laboratories reported revenue of ₹234.89 crore, up 50.15% year on year and 26.23% sequentially. Reported net profit was ₹31.03 crore, compared with ₹8.76 crore a year ago and ₹24.44 crore in June. These are parent-company figures, not consolidated group profit. Interim PAT excludes any deferred-tax adjustment, which the filing says will be provided at year end.

  • Source: standalone statement on PDF page 4 and notes on pages 13-14. Original ₹ lakh amounts are divided by 100 for crore; changes use original figures before display rounding. EPS is reported and not annualised.
  • Year ago is the quarter ended 30 Sep 2025; previous quarter is 30 Jun 2026. Standalone coverage is deliberate: the separate consolidated table is not mixed with this statement, and no owners-attributable group PAT is inferred.
  • The company says no deferred-tax adjustment has been made under Ind AS 12 because it will be provided at year end. This is a material basis limitation on the reported interim PAT; no normalised tax or adjusted PAT is estimated.
  • Exceptional expense of ₹0.58 crore relates to balances written back/written off on amounts no longer payable/receivable; it was ₹0.24 crore in June and nil a year ago. Reported PAT retains those items.
  • Reported standalone basic EPS is ₹3.57 versus ₹1.09 a year ago and ₹2.81 in June; diluted EPS is ₹3.56 versus ₹1.05 and ₹2.81. No per-share figures are inferred from closing capital.
  • Selected checked coverage from the original filing. Raw RSS notice time has no timezone suffix.

Checked 29 Oct 2026

Open original filing
Read the complete published results desk